This multicentre, randomised, double-blind, placebo-controlled, parallel-group study investigated the efficacy, safety and pharmacokinetics of remacemide hydrochloride in adult patients (n = 59) with refractory epilepsy, undergoing reduced or discontinued antiepileptic drug (AED) usage, as part of an evaluation for epilepsy surgery. On discontinuation or reduction of maintenance AEDs, patients received remacemide hydrochloride, up to 600 mg daily, or placebo, for up to ten days or until they experienced a fourth complex partial (CPS) or a generalised tonic-clonic (GTC) seizure. Pre-and post-study blood and urine samples were taken for analysis. Remacemide hydrochloride showed a significantly (P = 0.045) longer median time to fourth seizure compared with placebo (6.8 vs. 3.8 days). Median nine-day seizure counts were significantly (P = 0.0327) lower with remacemide hydrochloride than placebo (6.2 vs. 12.8). Eleven remacemide hydrochloride patients and six placebo patients completed ten days' treatment. Remacemide and desglycinyl metabolite levels were lower in patients receiving concomitant carbamazepine or phenytoin than in those receiving non-inducing AEDs or remacemide hydrochloride alone. No serious adverse events occurred; all patients receiving remacemide hydrochloride completed the study. Remacemide hydrochloride was well tolerated and showed significant therapeutic activity in this patient population.
INTRODUCTION
Remacemide hydrochloride is a novel anticonvulsant which is being developed for the treatment of epilepsy. The drug and its principal active desglycinyl metabolite are low-affinity, non-competitive N-methyl-D-aspartate (NMDA) antagonists 1, 2 . Both compounds are also potent sodium fast channel blockers. Remacemide hydrochloride is effective in a range of animal models suggesting broad anticonvulsant activity 1 .
Clinical studies with remacemide hydrochloride as adjunctive therapy, conducted in patients with medically refractory epilepsy, have shown a good safety and tolerability profile at doses of up to 1200 mg per day. Statistically significant differences in 50% responder rates compared to placebo have been shown at doses between 800 mg and 1200 mg per day 3, 4 . The purpose of this study was to assess the safety and efficacy of remacemide hydrochloride in the treatment of medically refractory epilepsy in patients who had concomitant AED therapy reduced or withdrawn as part of an evaluation for surgery. The pharmacokinetic profiles of remacemide and the desglycinyl metabolite were also evaluated in these patients.
PATIENTS AND METHODS

Patients
All patients were subject to complex partial seizures (CPSs) with or without secondary generalisation, as defined in the International Classification of Seizures 5 and had experienced at least four but not more than 16 CPSs during the last four days of the surgical evaluation period. Patients who had also experienced up to three generalised tonic-clonic (GTC) seizures during the same time period were eligible for admission. Interictal duration had to be greater than two hours.
Prior to entering the study, the patients' medical histories including seizure and AED history and AED withdrawal were recorded. The presence of localisation-related epilepsy was confirmed by EEG and the absence of a treatable lesion confirmed by computed tomography or magnetic resonance imaging. Patients were required to have undergone an ECG and a chest X-ray, within the previous year without significant findings.
Patients with significant psychiatric disorder or recurrent depression, progressive neurological disorders, a history of recurring status epilepticus while on adequate AED therapy, nonepileptic seizures within five years or any other serious medical disorder were excluded from the study. Also excluded were female patients at risk of pregnancy.
Written informed consent was obtained from each patient prior to the initiation of any study-related procedures, and the study was conducted in accordance with the principles of the Declaration of Helsinki and with the approval of the appropriate Institutional Review Board.
Study design
This was a randomised, double-blind, placebocontrolled, parallel-group study carried out at six centres in the USA. On completion of the presurgical evaluation, eligible patients were randomised to receive either remacemide hydrochloride or placebo for a period of up to ten days or until either the fourth CPS or GTC seizure from the beginning of day 2. Patients in the active group received remacemide hydrochloride four times daily. On day 1 they received a total of 450 mg calculated as remacemide free base (50 mg at 08.00 h, 100 mg at 12.00 h, 150 mg at 18.00 h and 150 mg at 22.00 h). On subsequent days they received four doses of 150 mg following the same dosing schedule, to provide a total daily dose of 600 mg remacemide hydrochloride. The control group received an equivalent number of matching placebo capsules.
A dose of lorazepam (according to body weight) was given at the start of day 1 to patients who experienced at least three CPSs or one GTC seizure within the 24 h immediately prior to randomisation. These patients received a further dose of lorazepam 12 h after the first dose. Lorazepam was then discontinued for the duration of the study.
Prior to receiving study treatment patients were given a physical examination, vital signs were recorded, blood and urine samples were taken for haematology, biochemistry, urinalysis, and where appropriate a pregnancy test was carried out. Neurological examinations were carried out daily throughout the treatment period. Baseline blood samples for analysis of remacemide and the desglycinyl metabolite were taken prior to the first dose on day 1.
Further blood samples were taken at trough and during the first dosing interval at 15, 30, 45, 60 and 90 min and two, three, four and six hours after dosing on days 3 and 7. Plasma samples were analysed using solid phase extraction followed by high performance liquid chromatography (HPLC) with ultraviolet (UV) detection at 210 nm. The limit of quantification for both remacemide and the desglycinyl metabolite in plasma was 10 ng/ml. On days 3 and 7, maximum plasma concentration (C max ), time to reach C max (t max ) and the area under the plasma concentration curve over the dosing interval (AUC 0−6 h ) were derived.
Statistical methods
All patients who remained in the study for at least 24 h from the point of randomisation and first dose of drug, were included in the analysis (the evaluable population). A patient completed the study upon having had four seizures between the beginning of day 2 and day 10, or upon reaching day 10 without experiencing a fourth seizure. The primary efficacy endpoint was the time to fourth seizure during ten days of therapy. All seizures were recorded but only CPS and GTC seizures which occurred in days 2 through 10 were counted toward meeting the 4-seizure exit criterion. Time-to-exit was analysed using the Gehan's generalised Wilcoxon statistic.
A further analysis was conducted on the evaluable population in which an extrapolated value of the number of seizures in nine days was estimated from the time-to-exit variable. For all the patients that completed the study, this value was derived from the ratio of seizure counts to time on study (from the beginning of day 2 until completing the study):
Nine-day value = 9 × No. of seizures starting from day 2 until completion No. of days in trial starting from day 2 .
The equation assigned a standard nine-day interval to each patient. The number of seizures placebotreated patients had, before leaving the study, was imputed for their seizure count in nine days; this provided the most conservative approach. This analysis ranked each patient dependent on the number of seizures experienced by that patient in nine days. The Wilcoxon rank sum test was applied to these ranks to test for treatment group differences. Similar analyses were also carried out on patients who completed the study. 
RESULTS
Sixty-one patients entered the study, 29 in the remacemide hydrochloride group and 32 in the placebo group. Four patients, all from the placebo group, failed to complete the study. One patient was withdrawn after six hours due to experiencing two GTCs which required parenteral intervention and one patient requested withdrawal after 17 h without stating a reason. These two patients were not included in the efficacy analysis as they did not complete the specified 24 h period following the first treatment. The other two patients remained in the study for sufficient time to be included in the evaluable population analysis. The investigator withdrew one of these patients after 28 h due to concern over a pre-study cardiac event and the other withdrew after three days due to anxiety about hospitalisation. These two patients were excluded from the completer population. Patient demographics are summarised in Table 1 . No significant differences were seen between the two treatment groups except for a significantly greater percentage of males in the remacemide hydrochloride group.
Clinical efficacy
Of the 59 patients included in the analysis, six placebo patients and nine remacemide hydrochloride patients had their concomitant AEDs completely withdrawn and received either remacemide hydrochloride monotherapy or placebo only. Of these, all but one patient (on placebo) reached the exit criterion of experiencing four seizures or completing ten days of treatment ( Table 2 ). The remaining patients continued to receive one or more concomitant AEDs (Table 3) . Compared with placebo, the remacemide hydrochloride group showed a statistically significantly longer median time to fourth seizure, in both the evaluable patient population (P = 0.045), and the study-completing population (P = 0.016) ( Table 4) . Furthermore, the extrapolated number of seizures in nine days in the remacemide hydrochloride group was statistically significantly lower than in the placebo group, in both the evaluable patient population (P = 0.033) and the study-completing population (P = 0.010) ( Table 4) .
Five non enzyme-induced patients (four of whom were receiving remacemide hydrochloride monotherapy) and six enzyme-induced patients completed the study without experiencing a fourth seizure, suggesting a comparable efficacy profile for remacemide hydrochloride in the presence or absence of hepatic enzyme induction. Eleven evaluable patients on remacemide hydrochloride and six patients on placebo completed ten days' treatment.
Pharmacokinetics
The mean pharmacokinetic parameters are summarised in Table 5 . The data indicate that plasma concentrations of remacemide and the desglycinyl metabolite were lower in patients who were assumed to be hepatically enzyme-induced due to taking concomitant carbamazepine or phenytoin than in those receiving non-inducing AEDs or remacemide hydrochloride alone. The mean AUC (0−6 h) values for remacemide and the desglycinyl metabolite were considerably smaller at steady-state concentrations for induced patients than for non-induced patients at both day 3 and day 7. a Patients exited the study after experiencing a fourth seizure or on completing day 10 without experiencing a fourth seizure. 
Adverse events
There were no serious or unexpected adverse events (AEs) and the overall incidence of AEs was similar in the remacemide hydrochloride and placebo groups (138 and 130 respectively). The most commonly reported events (>5% of patients across both treatment groups) were headache, somnolence, nausea, accident or injury, dyspepsia, dizziness, nervousness, tremor, vomiting, and ataxia (Table 6) . Dyspepsia was the only AE which showed a statistically significant difference between treatment groups. Six remacemide hydrochloride patients reported this event compared to one placebo patient (P = 0.022).
No patients withdrew from the study due to any AE which might have been attributable to remacemide hydrochloride. Mean baseline and exit values for all laboratory parameters were within normal ranges with the exception of gamma glutamyl transpeptidase (GGT) for which the mean value was 101.86 units per litre (U/L) for the placebo group and 83.07 U/L for the remacemide hydrochloride group, representing a mean baseline approximately 1.28 times the normal upper limit. While mean values for both groups rose slightly, to 113.3 U/L for placebo and 85.65 U/L for remacemide hydrochloride, more shifts were observed in the placebo patients. High baseline values for GGT are often observed in patients receiving enzyme-inducing AEDs. Some variations were seen in laboratory parameters in remacemide hydrochloride and placebo patients but were generally of a low magnitude and clinically unimportant. Five remacemide hydrochloride and three placebo patients experienced increases in alanine aminotransferase (ALT/SGPT). Decreases in red blood cell count (RBC) were seen in five remacemide hydrochloride patients accompanied by increases in lymphocyte count in three patients and a decrease in white cell count in one patient. None of the changes in laboratory parameters were considered clinically significant. No clinically significant changes were seen in vital signs.
DISCUSSION
Fifteen patients, nine in the remacemide hydrochloride group and six in the placebo group achieved total withdrawal from existing AED therapy prior to entering the study. The median time to exit was Analyses of data from all patients who completed at least 24 h in the study, and a separate analysis of those patients who reached the exit-point, showed statistically significant differences in favour of remacemide hydrochloride compared with placebo, both in the length of time to the fourth seizure, and in the extrapolated value for the number of seizures during days 2 to 10. These data support previous add-on studies which have shown remacemide hydrochloride to have therapeutic activity in patients with refractory epilepsy 3, 4 . Altogether, remacemide hydrochloride showed a two-fold improvement over placebo at a dose of 600 mg/day, a relatively low dose for enzymeinduced patients.
There were no serious AEs, and no patients in the remacemide hydrochloride group withdrew from the study. Variations were seen in some laboratory parameters in both remacemide hydrochloride and placebo patients. These were generally low in magnitude and were considered to be of no clinical importance.
Remacemide hydrochloride was well tolerated by the patients in this study. The qualitative and quantitative incidence of AEs was similar in the remacemide hydrochloride and placebo patient groups. Overall, our results indicate that remacemide hydrochloride has therapeutic activity in patients with medically refractive epilepsy at a dose of 600 mg/day. A subgroup of patients in which concomitant antiepileptic drugs were withdrawn completely, demonstrated a similar response, indicating the potential activity of remacemide hydrochloride as monotherapy.
There is an ethical dilemma concerning placebocontrolled monotherapy trials of new AEDs. It is generally unacceptable to withhold effective treatment from a patient with epilepsy. As a result, in the majority of studies, the drug under investigation is added to the drug already being taken as maintenance therapy. There may, however, be pharmacokinetic or pharmacodynamic interactions between the new drug and other drugs that prevent any confident interpretation of data from such studies as showing efficacy of the new drug as monotherapy. In an attempt to overcome these difficulties various approaches have been made to develop trial designs in which it might be ethically possible to subject individuals to no treatment or to sub-optimal treatment 6 .
The presurgical AED trial design was conceived to overcome the limitations of placebo-controlled monotherapy trials, while ensuring a high degree of patient safety 7 . At the time this study was conducted, all the authors believed that this design was important for proof of concept and initial monotherapy exploration, and contained effective patient safety provisions. However, even this design has some shortcomings, and the issue of monotherapy study methods continues to be debated 8, 9 . These criticisms do not undermine the scientific validity of the conclusion that remacemide was effective as monotherapy in this trial. At the present time, the optimal monotherapy trial design that satisfies both regulatory requirements and provides ethically acceptable 'best treatment' for patients remains a topic of discussion.
